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Original Article
Time to diagnosis of symptomatic
gastric and oesophageal cancer in
the Netherlands: Where is the room
for improvement?
NF van Erp1 , CW Helsper1, P Slottje2, D Brandenbarg3,
FL Büchner4, KM van Asselt5, JWM Muris6 , MF Kortekaas1,
PHM Peeters1 and NJ de Wit1
Abstract
Background: An efficient diagnostic pathway and early stage diagnosis for cancer patients is widely pursued. This
study aims to chart the duration of the diagnostic pathway for patients with symptomatic oesophageal and gastric
cancer, to identify factors associated with long duration and to assess the association of duration with tumour
stage at diagnosis.
Methods: This was a retrospective cohort study, using electronic health records of six routine primary care data-
bases covering about 640,000 patients, partly linked to the Netherlands Cancer Registry. Symptomatic patients with
oesophageal and gastric cancer (2010–2015) that presented in primary care were included. Duration of four diag-
nostic intervals was determined: patient interval; first symptoms to primary care consultation, primary care inter-
val; consultation to referral, secondary care interval; referral to diagnosis, and the diagnostic interval; consultation
to diagnosis. Characteristics associated with ‘long duration’ (P75 duration) were assessed using log-binomial
regression. Median durations were stratified for tumour stages.
Results: Among 312 symptomatic patients with upper gastrointestinal cancer, median durations were: patient
interval: 29 days (interquartile interval 15–73), primary care interval: 12 days (interquartile interval 1–43), secondary
care interval: 13 days (interquartile interval 6–29) and diagnostic interval: 31 days (11–74). Patient interval duration
was comparable for patients with and without alarm symptoms. Absence of cancer-specific alarm symptoms was
associated with ‘long duration’ of primary care interval and secondary care interval: relative risk 5.0 (95% confi-
dence interval 2.7–9.1) and 2.1 (95% confidence interval 1.3–3.7), respectively. Median diagnostic interval duration
for local stage disease was 51 days (interquartile interval 13–135) versus 27 days (interquartile interval 11–71) for
advanced stage (p¼ 0.07).
Conclusion: In the diagnostic pathway of upper gastrointestinal cancers, the longest interval is the patient interval.
Reducing time to diagnosis may be achieved by improving patients’ awareness of alarm symptoms and by diag-
nostic strategies which better identify cancer patients despite low suspicion.
Keywords
Upper gastrointestinal cancer, oesophageal cancer, gastric cancer, duration, diagnostic pathway, delay, general
practice, primary care
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Established knowledge before this study
• Prognosis of oesophageal and gastric cancer is highly dependent on disease stage at diagnosis.
• An efficient diagnostic pathway is key to timely diagnosis.
• To reduce time to diagnosis, more knowledge of interval duration, preventable delay and associations
between time to diagnosis and tumour stage is required.
What are the new findings?
• In the diagnostic pathway of oesophageal and gastric cancer patients in the Netherlands, the patient interval
is the longest, with comparable time to presentation in primary care for those with and without alarm
symptoms.
• For the majority of patients the median duration of the primary care and secondary care interval is relatively
short, especially for those with alarm symptoms, but 10–25% of the patients experience substantially long
duration of these intervals.
• Shorter time to diagnosis is seen for those with advanced disease stages, suggesting faster processing for
patients with poorer prognosis.
• Collaborative action with clinicians and researchers is needed to improve the diagnostic process, e.g. by
developing better test strategies, to better identify patients at risk for cancer, especially among those
without alarm symptoms.
Introduction
Upper gastrointestinal (UGI) cancer, i.e. oesophageal
and gastric cancer, has substantial morbidity and mor-
tality rates.1 Five-year overall survival rates range from
19–31% in non-metastatic UGI cancer, and for
patients with metastatic disease, median overall surviv-
al ranges from only 15–25 weeks.2–5
One of the explanations of this low level of
survival is the fact that UGI cancers are currently diag-
nosed in a relatively advanced disease stage; 70%
of the patients are diagnosed with stage III or IV
disease.6 This is besides the fact that these types
of cancers only become symptomatic in advanced
disease stages, and advanced stages may result from
delay either before presentation to healthcare services
in primary care or during diagnostic work-up in sec-
ondary care. According to the literature, shortening
the patient interval is probably most vital to reduce
delay in the diagnostic pathway of gastroesophageal
cancer.7,8
In gatekeeper systems like that in the Netherlands,
patients have to visit a general practitioner (GP) first
and GPs can refer patients to secondary care if needed.
Most patients with UGI cancer will therefore initially
present with symptoms in primary care. Referral to
secondary care is either made urgently (often through
telephone contact) or regularly (using a digital referral
system). Usually, GPs in the Netherlands have open
access to UGI endoscopy, meaning that they can
refer patients for this procedure without prior consul-
tation with a gastroenterologist.
Earlier studies reported on the duration of, and fac-
tors associated with, delay in different phases of the diag-
nostic pathway, providing ‘fragmented’ evidence.8–16
Delaying factors include symptom recognition and
interpretation, patient characteristics and healthcare
factors.9,17 Although several studies reported on the
association between time to diagnosis and tumour
stage at diagnosis and/or survival, they considered indi-
vidual intervals of the diagnostic pathway, hampering
solid conclusions.11,12,18,19 To improve the diagnostic
pathway of UGI cancers, a comprehensive overview
of the duration of its intervals and factors contributing
to delay is required. The aim of this study is to provide
this overview of the duration of the diagnostic pathway
for patients with oesophageal and gastric cancer in the
Netherlands, to assess characteristics associated with
long duration, and to assess the association between
duration and tumour stage at diagnosis.
Methods
Study design and data source
A retrospective cohort study was performed using
anonymised data from six academic general practice
networks (Supplementary Material Appendix 1), con-
taining coded and free-text information from primary
care electronic health records (EHRs) of over 640,000
patients. Free texts include real-time registrations of
patient consultations, i.e. presented complaints, results
of physical examination, clinical reasoning of the GP
and management plan. This data source was used to
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determine the duration of the patient interval (IP) and
the primary care interval (IPC).
To be able to determine the secondary care interval
(ISC), the diagnostic interval (ID) and the association
between duration and tumour stage at diagnosis, we
linked, where possible, the routine primary care data
to the data of the Netherlands Cancer Registry (NCR).
The NCR is a population-based registry with detailed
diagnostic and therapeutic data of over 95% of Dutch
cancer patients since 1989.20 Data linkage was possible
for three of the six databases (Julius General
Practitioner’s Network database (Utrecht) (JGPN),
Academic Network of General Practice database
(Amsterdam VUmc) (ANH VUmc) and Registration
Network Groningen (RNG): together comprising
76% of the cancer patients) as these include pseudo-
nyms based on patient identifiers. Primary care and
NCR records were linked based on date of birth, sex
and postal code (six digits) among patients with the
cancer type in question, using a trusted third-party
linkage procedure to comply with privacy regulations
of Dutch and International law (General Data
Protection Regulation, https://gdpr.eu).
Case selection
All adult patients (aged 18 years) registered with
the International Classification of Primary Care
(ICPC, version 1)21 code for ‘malignant neoplasm of
oesophagus’ (D77.01) or ‘malignant neoplasm of stom-
ach’ (D74) in 2010–2015 were extracted from the pri-
mary care databases.
Of all identified patients, we checked the free text
elements of the EHR to confirm the cancer diagnosis,
based on summaries of correspondence from secondary
care and other descriptions indicating cancer presence.
Only those patients with a confirmed cancer diagnosis
were included. Next, we selected only those who pre-
sented to the GP with symptoms, and were referred by
the GP for diagnostic workup.
Data collection
Data were collected from the primary care databases
and NCR by medically trained researchers (6th year
medical students). Primary care EHRs were scrutinised
manually from 5 years before the date of entry of the
ICPC code for UGI cancer up to 1 year after. EHRs
were studied up to 1 year after ICPC coding because
the date of the ICPC code marks the beginning of the
disease episode and not the actual date of diagnosis as
registered in the NCR.
Four time intervals of the diagnostic pathway were
assessed (Figure 1), based on the definitions provided
in the Aarhus statement.22 The IP was defined as the
time interval between first noticing cancer-related
symptom(s) to first consultation for these symptoms
in primary care; the IPC was defined as duration
from first consultation with cancer-related signs and/
or symptoms in primary care to referral to secondary
care; the ISC was defined as duration from referral to
secondary care by the GP to date of histological diag-
nosis, and the overarching ID was defined as duration
from first consultation to date of diagnosis. Definitions
of the different milestones are shown in Table 1.
Patient and presentation characteristics were collect-
ed from the routine primary care data. All character-
istics and methods of collection are shown in
Supplementary Material Appendix 3. Symptoms were
categorised as UGI cancer-specific alarm symptoms
(persistent vomiting, haematemesis or melaena, dyspha-
gia and a palpable mass in the epigastric region),23
cancer general alarm symptoms (unintended weight
loss, anaemia and ascites) and non-alarming symptoms
(all other UGI cancer-related symptoms). Disease char-
acteristics were retrieved from the NCR data for NCR
matched patients.
Analyses
Duration of the four intervals was calculated and strat-
ified for several patient and presentation characteristics
and tumour stage at diagnosis. We consistently added
one day to all durations, as we considered same-day
proceedings as a duration of one day. Differences in
median duration were tested with the Mann-Whitney U
test for variables with two categories or the Kruskall-
Wallis test for variable with 3 categories.
To assess associations with ‘long duration’, we
defined this as duration equal to or longer than the
75th percentile value (P75) of duration for the differ-
ent intervals (IP, IPC, ISC). Univariable and multivar-
iable log-binomial regression analyses were performed
to identify characteristics associated with ‘long dura-
tion’. Characteristics that were statistically significantly
associated with ‘long duration’ (p<0.05) in univariable





Figure 1. The cancer diagnostic pathway and its intervals,
based on the Aarhus statement.22
ID: diagnostic interval; IP: patient interval; IPC: primary care
interval; ISC: secondary care interval.
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analysis were included in multivariable analysis, next to
age and sex. For IPC, we assessed extra characteristics
(consultation frequency, chronic comorbidities and
psychiatric comorbidity).
Software
Data transformation and analyses were performed in
SPSS version 22.0 (SPSS Inc., Chicago, Illinois, USA).
Patient and public involvement
Patients and/or public were not involved in this study.
Results
Patient characteristics
Of 676 patients with an ICPC code for oesophageal
and gastric cancer, 312 patients (46%) met the eligibil-
ity criteria; 174 oesophageal and 138 gastric cancer
patients. The most common reasons for exclusion
(Figure 2) were a non-confirmed cancer diagnosis
(potentially incorrect ICPC code) and an unclear diag-
nostic pathway (plausible diagnosis but unclear route
to diagnosis).
Patient characteristics are described in Table 2.
Most of the patients (64%) were male: 70% of the
oesophageal cancer patients and 55% of the gastric
cancer patients. Mean age at first GP consultation
was 66.4 years (standard deviation (SD) 11.9), compa-
rable for oesophageal and gastric cancer. During the
first consultation, for around 60% of the patients a
cancer-specific alarm symptom was registered: 67% of
the oesophageal cancer patients and 54% of the gastric
cancer patients.
For the analysis of ISC, ID and the association of
duration with tumour stage, a total of 237 patients
(76% of eligible) could be linked to the NCR. For
172 patients (73% of those linked) a match was
found in the NCR. We found no differences in patient
and presentation characteristics between those match-
ing NCR (n¼ 172) and those who did not match
(n¼ 65) (Supplementary Material Appendix 4). Of
NCR-matched patients, 122 (71%) were diagnosed
with advanced disease stage (stage III or IV): 80%
among oesophageal cancer patients and 54% among
gastric cancer patients.
Duration of time intervals
Duration of the different intervals is shown in Table 3.
All intervals showed a right skewed distribution as
shown in Figure 3, with a strong increase in durations
for 10–25% of patients with the longest intervals.
Table 1. Milestones of the diagnostic pathway of symptomatic cancer and their definitions.
Definition
Date of first symptom(s) Date of first symptom(s) was defined as registered by the GP in the free-text fields of the
electronic health record. If ‘stomach ache since one week’ was registered, date of first
symptom was the date 7 days before the date of first consultation. Less strictly described
durations, such as ‘several weeks’ and ‘a couple of days’ were interpreted according to
predefined rules, Supplementary Material Appendix 2. Duration indications as ‘for a while’ or
‘for some time’ where considered too vague for interpretation and were excluded from IP
analysis. In case of different duration indications for multiple cancer related complaints, the
longest duration was selected to determine IP duration.
Date of first consultation Date of first consultation was defined as the first presentation to the GP with signs or symptoms
related to the UGI cancer. In case of vague or non-specific signs or symptoms, the first
consultation with complaints that eventually led to the cancer diagnosis, and could rea-
sonably be related to the cancer, was taken. We minimised the risk of misattribution of
symptoms by discussing doubtful cases in our team of researchers, who are medical doctors
with primary care experience.
Date of referral Date of referral was defined as the moment the responsibility for the patient was transferred
from primary to secondary care, as registered in the electronic health record. Referral to
radiology or endoscopy department for imaging was considered as referral if abnormal
findings subsequently resulted in referral to a specialist, without further interference of the
GP. In case of multiple referrals to, or cross-referrals in secondary care, the first referral for
further exploration of cancer related symptoms was taken.
Date of diagnosis To determine ISC and ID duration, the date of diagnosis was retrieved from the NCR for NCR
matched patients. The NCR uses the hierarchy for diagnosis date as provided by the
European Network of Cancer Registries, primarily registering date of histological diagnosis.
GP: general practitioner; ID: diagnostic interval; IP: patient interval; ISC: secondary care interval; NCR: the Netherlands Cancer Registry; UGI:
upper gastrointestinal.
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An IP) was reported for 201 patients (64%). It
could not be determined for 29% and 43% of oesopha-
geal and gastric cancer patients, respectively. The
median duration of IP was 29 days (interquartile inter-
val (IQI) 15–73), 31 days (IQI 22–76) for oesophageal
cancer and 25 days (IQI 15–62) for gastric cancer.
Although statistically non-significant, longer IP
durations were seen for younger patients. Patients
without alarm symptoms had the shortest median
IP duration (22 days (IQI 12–62)), those with general
cancer alarm symptoms the longest (46 days (IQI
22–92)).
Adult patients with incident ICPC code for
oesophageal - or gastric cancer between
2010 and 2015
n = 676
Symptomatic presentation and referral by GP
n = 312
Linked to Netherlands Cancer Registry
(JGPN, RNG and ANH VUmc)
n = 237
Matched with Netherlands Cancer Registry
n = 172





















Excluded based on free-texted assessment
n = 364 (53.8%)
No confirmed cancer diagnosis, n = 139 (20.6%)
Diagnosis outside 2010–2015, n = 31 (4.6%)
First presentation in secondary care, n = 39 (5.8%)
First presentation in emergency setting, n = 16 (2.4%)
First presentation abroad, n = 10 (1.5%)
Cancer is an incidental finding, n = 25 (3.7%)
Unclear diagnostic pathway, n = 97 (14.3%)
Other (double patient...) n = 7 (1.0%)
Figure 2. Identified upper gastrointestinal cancer cases and reasons for exclusion.
ANH VUmc: Academic Network of General Practice database (Amsterdam VUmc); GP: general practitioner; HAGnet AMC: General
Practice Registration Network (Amsterdam AMC); ICPC: International Classification of Primary Care; ID: diagnostic interval; IP:
patient interval; IPC: primary care interval; ISC: secondary care interval; JGPN: Julius General Practitioner’s Network database
(Utrecht); RNFM: Research Network Family Medicine (Maastricht); RNG: Registration Network Groningen; RNUH-LEO: Registration
Network of General Practitioners Associated with Leiden University (Leiden).
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The median duration of the IPC was 12 days (IQI 1–
43), it was 8 days (IQI 1–38) for oesophageal cancer
and 14 days (IQI 1–51) for gastric cancer patients.
Although statistically non-significant, women had a
longer duration of 15 days (IQI 1–45) as compared to
8 days (IQI 1–43) for men. The shortest durations were
seen for patients with UGI-specific cancer-alarm symp-
toms: 1 day (IQI 1–12), as compared to 11 days (IQI 3–
46) and 32 days (IQI 13–98) for patients with general
cancer alarm symptoms and patients without alarm
symptoms, respectively (p<0.01). For gastric cancer,
patients under 55 years showed statistically significant
longer median duration to referral of 40 days (IQI 16–
130) as compared to 8 days (IQI 1–40) for patients aged
75 years and older, p¼ 0.01.
The median duration of the ISC was 13 days (IQI 6–
29), with shortest durations for those with cancer-
specific alarm symptoms (8 days, IQI 5–24) (Table 2).
Median duration of the ID was 31 days (IQI 11–74): 23
days for oesophageal cancer (IQI 8–60) and 44 days
(IQI 20–145) for gastric cancer. Patients with UGI
cancer-specific alarm symptoms showed the shortest







Population n (%) 312 (100) 174 (100) 138 (100)
Male patients n (%) 199 (63.8) 123 (70.7) 76 (55.1)
Age at first consultation Mean SD 66.4 11.9 66.6 10.2 66.2 13.8
SES score 2014a Mean SD 0.32 1.17 0.39 1.14 0.23 1.22
Missing, n (%) 66 (21.2) 33 (19.0) 33 (23.9)
Consultation frequency in year
before first consultation
Median (IQI) 5 (2–10) 5 (2–8) 6 (2–12)
Missing, n (%) 24 (7.7) 9 (5.2) 15 (10.9)
Number of registered chronic
somatic comorbiditiesb
Median (IQI) 3 (1–5) 3 (1–6) 3 (1–4)
Missing, n (%) 8 (2.6) 8 (4.6) 0 (0.0)
Registered psychiatric comorbidityb n (%) 65 (20.8) 40 (23.0) 25 (18.1)
Missing, n (%) 8 (2.6) 8 (4.6) 0 (0.0)
Dominant symptom(s) at first consultationc
Cancer-specific alarm symptom(s) n (%) 127 (40.7) 86 (49.4) 41 (29.7)
Cancer general alarm symptom(s) n (%) 61 (19.6) 25 (14.4) 36 (26.1)
Other, non-alarming symptoms n (%) 124 (39.7) 63 (36.2) 61 (44.2)
Dominant symptom(s) at referralc
Cancer-specific alarm symptom(s) n (%) 191 (61.2) 117 (67.2) 74 (53.6)
Cancer general alarm symptom(s) n (%) 69 (22.1) 24 (13.8) 45 (32.6)
Other, non-alarming symptoms n (%) 52 (16.7) 33 (19.0) 19 (13.8)
Population linked to NCRd n (%) 237 (76.0) 138 (79.3) 99 (71.7)
Match with NCR n (% of linked) 172 (72.6) 111 (80.4) 61 (61.6)
TNM disease stage at diagnosis
0, I or II n (% of matched) 42 (24.4) 19 (17.1) 23 (37.7)
III or IV n (% of matched) 122 (70.9) 89 (80.2) 33 (54.1)
Missing n (% of matched) 8 (4.7) 3 (2.7) 5 (8.2)
Morphology
Adenocarcinoma n (% of matched) 93 (54.1) 57 (51.4) 36 (59.0)
Squamous cell carcinoma n (% of matched) 42 (24.4) 42 (37.8) –
Other n (% of matched) 37 (21.5) 12 (10.8) 25 (41.0)
ANH VUmc: Academic Network of General Practice database (Amsterdam VUmc); IQI: interquartile interval; JGPN: Julius General Practitioner’s
Network database (Utrecht); NCR: the Netherlands Cancer Registry; RNFM: Research Network Family Medicine (Maastricht); RNG: Registration
Network Groningen; SD: standard deviation; SES: socio-economic status; TNM: tumour node metastasis.
aSES scores of 2014, based on level of education, income and job status. The Dutch mean SES in 2014 was 0.28 (SD 1.09). SES could be derived for
patients from four out of the six primary care network databases (JGPN, ANH VUmc, RNG and RNFM).
bAccording to the definitions of O’Halloran et al.34
cCancer-specific alarm symptoms for UGI cancers (oesophageal and gastric cancer) were defined as persistent vomiting, UGI bleeding (hae-
matemesis or melaena), dysphagia and a palpable mass in the epigastric region. Cancer-general alarm symptoms were defined as unintended
weight loss, anaemia and ascites. Other, non-alarming symptoms were all other presenting symptoms that could be related to the UGI cancer,
including abdominal pain, nausea, gastro-oesophageal reflux, malaise etc. In case of presence of both cancer-specific and cancer-general alarm
symptoms, cancer-specific alarm symptoms were considered dominant.
dLinkage with NCR was possible for three of the six primary care network databases (JGPN, ANH VUmc and RNG).
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ID durations (Table 2). Four patients, who showed
negative durations of the ISC, suggesting registration
errors, were excluded from ISC and ID analyses.
Results of the log-binomial regression analyses for
association with ‘long duration’ (P75) of the respective
intervals are shown in Table 4. Please note; the absolute
number of days that the 75th percentile (cut-off for ‘long
duration’) represents, differs for each interval. In short:
for IP, no characteristics were found to be statistically
significantly associated with ‘long duration’. For IPC,
patients without cancer-specific alarm symptoms
showed a higher risk for ‘long duration’ in multivariable
analysis (RR 5.0, 95% CI 2.7–9.1). For ISC, patients
with cancer general alarm symptoms showed a higher
risk for ‘long duration’ in multivariable analysis (RR
2.1, 95% CI 1.3–3.7).
Association of duration with tumour stage at
diagnosis
For NCR-matched patients (n¼ 172), duration of the
respective intervals according to disease stage are
shown in Table 3. Median IP and IPC durations were
shorter (though not statistically significant) for patients
with localised disease (stage 0, I or II) as compared to
patients with advanced disease (stage III and IV).
Median ISC duration was longer (20 days, versus 10
days, p-value: 0.04) for patients with local disease as
compared to patients with advanced disease stage.
Median ID duration was almost twice as long for
those with local disease as compared to patients with
advanced disease stage (51 days, versus 27 days,
p-value: 0.07). At first GP consultation, 54 of 122
(44.3%) patients with advanced disease stage had
cancer-specific alarm symptoms, as compared to 15 of
42 patients (35.7%) with localised disease
(Supplementary Material Appendix 5).
Discussion
Summary of the main findings
In the diagnostic pathway of patients with UGI cancer,
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Figure 3. Distribution of the duration of the different intervals of the cancer diagnostic pathway of upper gastrointestinal (UGI)
cancer patients.
ID: diagnostic interval; IP: patient interval; IPC: primary care interval; ISC: secondary care interval.
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and comparable for patients with and without alarm
symptoms. Intervals in both primary and secondary
care were relatively short, with a median duration of
12 and 13 days respectively. The median duration of
the overall ID was 31 days; 23 days for oesophageal
cancer and 44 days for gastric cancer. In all intervals,
10–25% of the patients showed a relatively long dura-
tion. Absence of cancer-specific alarm symptoms was
associated with ‘long duration’ (P75) for both IPC
and ISC. We found shorter durations of ISC and ID
for patients with advanced disease stages.
Strengths and limitations
Strengths and limitations of the use of routine primary
care data have previously been discussed elsewhere.24
The main strength of the current dataset is the avail-
ability of free-text annotations of all GP consultations,
as this provides detailed insight in the diagnostic pro-
cess, including GP considerations and contextual fac-
tors. We chose not to censor the length of any of the
intervals at a maximum time period, as done in previ-
ous studies, as the free-text registrations confirmed that
some interval durations are very long for plausible rea-
sons. Furthermore, linkage of primary care data to a
national cancer registry (NCR), allowed us to analyse
all intervals of the diagnostic pathway in one study.
Limitations include the number of excluded
patients. This includes patients for whom the ICPC
code for UGI cancer was not supported by the free-
text registrations (20% of UGI cancer ICPC codes).
Reasons for not being able to verify these diagnoses
varied from lacking information to clearly incorrect
use of the ICPC code (e.g. cancer diagnostic code
used for a positive family history of cancer or for
other UGI complaints). It has been shown earlier
that, when cancer registry-based validation is per-
formed, up to half of the ICPC codes for cancer in
primary care records turn out to be incorrectly assigned
(‘false positive’).25 As we were not able to link all
patients to the NCR for diagnostic confirmation, we
choose to strictly include only those patients for
whom the free text of the primary care record con-
firmed the UGI cancer diagnosis. Furthermore, we
excluded patients with unclear diagnostic pathways
(14%) and those presenting in emergency settings
(2%). This may have affected our findings as, for exam-
ple, unclear pathways may be more likely for very short
or very long diagnostic intervals. Also, patients diag-
nosed in emergency settings may include patients that
could have been referred from primary care and may
have more had advanced tumour stages.26
We were able to link 76% of eligible patients to the
NCR, enabling ISC and ID duration assessment. For
the remaining 24% of patients linkage was not
possible, because some of the primary care databases
used did not contain the right pseudonyms for data-
linkage (pseudonym based on postal code, birthdate
and sex). As we used the primary care record to
verify the UGI cancer diagnosis, we were quite certain
of the presence of cancer. However, of the patients for
whom linkage could be performed, not all patients
(73%) matched with the NCR. We hypothesise that
the main reasons for not matching the NCR were
changes of postal codes (patients who moved between
registry at GP and at registration in NCR) and typo-
graphic errors. Even though matching and non-
matching patients did not differ substantially with
respect to patient- and presentation characteristics,
‘non-matching’ may have been not random, e.g. in
cases of ‘patients with changing postal-codes’.
Furthermore, identifying the first presentation with
cancer-related symptoms in open-text fields of primary
care data is challenging, especially in cases of vague or
less specific symptoms. Even though our approach has
limitations, we believe it is more accurate than the sole
use of diagnostic codes or retrospective questionnaires
to identify a first presentation. Free text availability
enables the retrieval of a broad range of potential
first symptoms, registered at the time of occurrence,
which can be extracted from a larger body of daily
care registrations. We minimised the risk of misattribu-
tion of symptoms by discussing doubtful cases in our
team of researchers with primary care experience.
Accurate measurement of the patient interval is
known to be challenging and the methods we used
come with some limitations.22,27,28 The registration of
symptom duration in the EHR is a reflection of the
GP’s interpretation of the duration that the patient
remembered and mentioned. Inaccurate or lacking reg-
istration may occur and missing duration information
is potentially selective, as doctors may be more prone
to register either remarkably short or long durations.
We found 29% and 43% missing patient intervals
among oesophageal and gastric cancer patients, respec-
tively. Less specific registrations of IP durations also
occurred, for which we used a standardised approach
to approximate duration (definitions in Supplementary
Material Appendix 2). Therefore, whereas IPC, ISC
and ID duration should be trusted to the day, IP
medians should be seen as an approximation of
duration.
Comparison with existing literature and
implications
We found longer median IP durations than earlier
reports in the UK, that described median durations
of 21.5 days (IQI 7–46) for oesophageal cancer and
9 days (IQI 0–38) for gastric cancer.8,13 Even though
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previous studies suggest that patients consult the GP
earlier when their symptoms are more serious (like pain
or bleeding),9 our findings indicate that patients
may not be fully aware of alarm symptoms, since dura-
tions of the patient interval for patients with and with-
out registered alarm symptoms were comparable.
We believe that raising patients’ awareness of UGI
cancer alarm symptoms may be the most efficient
way to improve prompt presentation and shorten
time to diagnosis. Getting more insight in reasons for
postponing consultation would be required for a tar-
geted approach.
Previously reported median durations of IPC range
from 1 day (IQI 0–32) for oesophageal cancer16 to 12
days for gastric cancer (IQI 0–65);13 some were slightly
shorter than the IPC durations we found. The main
factor earlier reported to be associated with ‘delay’ in
primary care is an ‘initial misdiagnosis’.9 Even though
this sounds as an avoidable and even blameworthy
reason for delay, it may be seen as a reflection of risk
assessment and the gatekeeping role of the GP. Our
finding that absence of alarm symptoms was associated
with ‘long duration’ in primary care is in line with this.
Improving timely detection of cancer among patients
without alarm symptoms is challenging, given the high
incidence of common UGI symptoms and low risk of
cancer.29 Simply lowering the threshold for referral is
not the solution for reducing time to referral: apart
from the increasing risk of non-indicated endoscopies
with normal results, there is already a growing demand
for diagnostic services in secondary care. We believe
that development of novel diagnostic strategies for
patients with less-specific symptoms in primary care is
needed, either based on improved selection of patients
at risk (for example by decision support tools derived
through artificial intelligence in big databases), on the
application of diagnostic tests (like the cytosponge for
Barrett’s oesophagus, presently evaluated in the UK)
or on the use of new biomarkers for gastric and oeso-
phageal cancer.30 Since 10–25% of the patients show a
strong increase in time to referral, there also is a need
for in-depth exploration of the reasons for very long
primary care intervals.
Compared to previous UK studies, we found shorter
or comparable median durations of ID. Din et al.
reported median ID durations of 83 days (IQI 35–207)
and 84 days (IQI 35–199) for oesophageal and gastric
cancer respectively,14 while Swann et al. reported com-
parable durations of 28 days (IQI 12–66) and 42 days
(IQI 17–89).16 Even though these differences may be
partly explained by different research methods used,
they probably reflect true and notable differences in
ID durations between different healthcare systems, soci-
eties and time periods. This deserves further
international comparison, since it could provide clues
for reducing the time to diagnosis.
Whether reduction of the duration of the intervals in
the diagnostic pathway would improve clinical out-
comes is uncertain. Some earlier studies showed that
increased durations of ID were associated with
advanced disease stage or worse clinical outcomes.19,31
In contrast, we found longer durations of both ISC and
ID, for patients diagnosed with local disease stage
(stage 0, I or II). As slightly more patients with
advanced disease stage had specific alarm symptoms,
we believe that for the majority of patients this reflects
an adequately functioning healthcare system, with
quick response for those who are most in need. This
concept; long duration for early stage disease, is known
as the ‘waiting time paradox’.32 Truly understanding
the association between time to diagnosis and stage at
diagnosis is complex. It has been shown before that the
association between waiting times and disease stage or
clinical outcomes is not simply linear and that obser-
vational studies are not the ideal design for assessment
of this association.33 More refined methodology is
required to enable future studies to unravel the com-
plex association between duration and tumour stage
for these cancer types.
Conclusion
In the diagnostic pathway of UGI cancers, the longest
interval is the IP, equally long for patients with and
without cancer alarm symptoms. A relatively short
ID, especially for those with alarm symptoms and
those with advanced disease, suggests faster processing
for the sickest patients. Durations of the IPC and ISC
are generally acceptable, but nonetheless, remarkably
long for 10–25% of the cancer patients. Apart from
improving patients’ awareness of alarm symptoms, fur-
ther reduction of delay in diagnosing UGI cancer may
be feasible by introducing novel diagnostic strategies
for cancer patients with gastrointestinal symptoms
who are currently considered at low risk because of
‘low suspect’ clinical presentation.
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